参考文献/References:
[1]Richette P,Doherty M,Pascual E,et al.2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout[J].Ann Rheum Dis,2020,79(1):31-38.[2]Kumar M,Manley N,Mikuls TR.Gout Flare Burden, Diagnosis, and Management: Navigating Care in Older Patients with Comorbidity[J].Drugs & Aging,2021,38(7):545-557. [3]Singh JA.Disease modification in gout: a qualitative study of gout expert rheumatologists[J].Rheumatol Adv Pract,2022,6(1):rkab107.[4]Richette P,Doherty M,Pascual E,et al.2016 updated EULAR evidence-based recommendations for the management of gout[J].Ann Rheum Dis,2017,76:29-42.[5]McKenzie BJ,Wechalekar MD,Johnston RV,et al.Colchicine for acute gout[J].Cochrane Database Syst Rev,2021,8(8):CD006190. [6]Cozza J,Do TVC,Ganti S,et al.The Ugly Side of Colchicine[J].J Investig Med High Impact Case Rep,2021,9:23247096211029744.[7]Sriranganathan MK,Vinik O,Pardo Pardo J,et al.Interventions for tophi in gout[J].Cochrane Database Syst Rev,2021,8(8):CD010069.[8]Liu CW,Chang WC,Lee CC,et al.The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia-A systematic review and meta-analysis[J].Nutr Metab Cardiovasc Dis,2019,29(10):1011-1022.[9]Neogi T,Jansen TL,Dalbeth N,et al.2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Ann Rheum Dis,2015,74(10):1789-1798. [10]Matsushita K,Mahmoodi BK,Woodward M,et al.Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate[J].JAMA,2012,307(18):1941-1951.[11]Yin R,Li L,Zhang G,et al.Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis[J].BMJ Open,2018,8(4):e017542. [12]Medani S,Wall C.Colchicine toxicity in renal patients-Are we paying attention?[J].Clin Nephrol,2016,86(2):100-105. [13]Alkadi H,Khubeiz MJ,Jbeily R.Colchicine: A Review on Chemical Structure and Clinical Usage[J].Infect Disord Drug Targets,2018,18(2):105-121.[14]Vargas-Santos AB,Neogi T.Management of Gout and Hyperuricemia in CKD[J].Am J Kidney Dis,2017,70(3):422-439.[15]Zhu Y,Pandya BJ,Choi HK.Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008[J].Am J Med,2012,125:679-687. [16]Krishnan E.Reduced glomerular function and prevalence of gout: NHANES 2009-2010[J].PLoS One,2012,7:e50046. [17]Saag KG,Becker MA,Whelton A,et al.Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study[J].Arthritis Rheumatol,2019,71(1):143-153. [18]Gunawardhana L,Becker MA,Whelton A,et al.Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment:phase II placebo-controlled study[J].Arthritis Res Ther,2018,20(1):99. [19]Yang AY.Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases[J].Int J Clin Pharmacol Ther,2020,58(1):21-28.[20]Hu AM,Brown JN.Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review[J].Clin Rheumatol,2020,39(11):3287-3294.[21]Chou HW,Chiu HT,Tsai CW,et al.Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study[J].Nephrol Dial Transplant,2018,33(9):1620-1627. [22]Liu X,Wang H,Ma R,et al.The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5[J].Clin Exp Nephrol,2019,23(3):362-370.[23]Liang N,Sun M,Sun R,et al.Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort[J].Arthritis Res Ther,2019,21(1):200. [24]Yamanaka H,Tamaki S,Ide Y,et al.Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study[J].Ann Rheum Dis,2018,77(2):270-276.
相似文献/References:
[1]刘 星,刘璟琰,张思宇.维生素C联合非布司他对高尿酸血症伴痛风患者sICAM-1及尿酸的影响[J].医学信息,2020,33(07):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
LIU Xing,LIU Jing-yan,ZHANG Si-yu.Effects of Vitamin C Combined with Febuxostat on sICAM-1 and Uric Acid in Patients with Hyperuricemia and Gout[J].Journal of Medical Information,2020,33(18):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
[2]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Journal of Medical Information,2020,33(18):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
[3]李凤敏,顾玲玲,付建茹.非布司他与别嘌醇治疗高尿酸血症伴痛风的疗效比较[J].医学信息,2022,35(01):165.[doi:10.3969/j.issn.1006-1959.2022.01.041]
LI Feng-min,GU Ling-ling,FU Jian-ru.Comparison of Febuxostat and Allopurinol in the Treatment of Hyperuricemia with Gout[J].Journal of Medical Information,2022,35(18):165.[doi:10.3969/j.issn.1006-1959.2022.01.041]